

REFERENCIAS

13. Referencias

- Abramov A.Y., Canevari L. y Duchon M.R. (2004). Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. *J Neurosci* 24(2): 565-75.
- Aksenov M.Y., Tucker H.M., Nair P., Aksenova M.V., Butterfield D.A., Estus S. y Markesbery W.R. (1998). The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. *J Mol Neurosci* 11(2): 151-64.
- Aksenov M.Y., Tucker H.M., Nair P., Aksenova M.V., Butterfield D.A., Estus S. y Markesbery W.R. (1999). The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease. *Neurochem Res* 24(6): 767-74.
- Allain H., Bentue-Ferrer D., Tribut O., Gauthier S., Michel B.F. y Drieu-La Rochelle C. (2003). Alzheimer's disease: the pharmacological pathway. *Fundam Clin Pharmacol* 17(4): 419-28.
- Allain H., Bentue-Ferrer D., Zekri O., Schuck S., Lebreton S. y Reymann J.M. (1998). Experimental and clinical methods in the development of anti-Alzheimer drugs. *Fundam Clin Pharmacol* 12(1): 13-29.
- Alzheimer A. (1907). Über eine eigenartige Erkrankung der Hirnrinde. *Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin* 64: 146-148.
- Amtul Z., Lewis P.A., Piper S., Crook R., Baker M., Findlay K., Singleton A., Hogg M., Younkin L., Younkin S.G., Hardy J., Hutton M., Boeve B.F., Tang-Wai D. y Golde T.E. (2002). A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. *Neurobiol Dis* 9(2): 269-73.
- Anandatheerthavarada H.K., Biswas G., Robin M.A. y Avadhani N.G. (2003). Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. *J Cell Biol* 161(1): 41-54.
- Anderson S., Bankier A.T., Barrell B.G., de Bruijn M.H., Coulson A.R., Drouin J., Eperon I.C., Nierlich D.P., Roe B.A., Sanger F., Schreier P.H., Smith A.J., Staden R. y Young I.G. (1981). Sequence and organization of the human mitochondrial genome. *Nature* 290(5806): 457-65.
- Anderton B.H. (2002). Ageing of the brain. *Mech Ageing Dev* 123(7): 811-7.
- Andrews R.M., Kubacka I., Chinnery P.F., Lightowlers R.N., Turnbull D.M. y Howell N. (1999). Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. *Nat Genet* 23(2): 147.
- Arendt T. (2000). Alzheimer's disease as a loss of differentiation control in a subset of neurons that retain immature features in the adult brain. *Neurobiol Aging* 21(6): 783-96.
- Arendt T., Holzer M., Bruckner M.K., Janke C. y Gartner U. (1998). The use of okadaic acid in vivo and the induction of molecular changes typical for Alzheimer's disease. *Neuroscience* 85(4): 1337-40.
- Arnheim N. y Cortopassi G. (1992). Deleterious mitochondrial DNA mutations accumulate in aging human tissues. *Mutat Res* 275(3-6): 157-67.

referencias

- Asthana S., Baker L.D., Craft S., Stanczyk F.Z., Veith R.C., Raskind M.A. y Plymate S.R. (2001). High-dose estradiol improves cognition for women with AD: results of a randomized study. *Neurology* 57(4): 605-12.
- Bacskai B.J., Klunk W.E., Mathis C.A. y Hyman B.T. (2002). Imaging amyloid-beta deposits in vivo. *J Cereb Blood Flow Metab* 22(9): 1035-41.
- Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D. y Yednock T. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. *Nat Med* 6(8): 916-9.
- Barrientos A., Casademont J., Cardellach F., Estivill X., Urbano-Marquez A. y Nunes V. (1997). Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. *Brain Res Mol Brain Res* 52(2): 284-9.
- Barrientos A., Casademont J., Rotig A., Miro O., Urbano-Marquez A., Rustin P. y Cardellach F. (1996). Absence of relationship between the level of electron transport chain activities and aging in human skeletal muscle. *Biochem Biophys Res Commun* 229(2): 536-9.
- Beal M.F. (1992). Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? *Ann Neurol* 31(2): 119-30.
- Beal M.F. (1995). Aging, energy, and oxidative stress in neurodegenerative diseases. *Ann Neurol* 38(3): 357-66.
- Beal M.F. (1996). Mitochondria, free radicals, and neurodegeneration. *Curr Opin Neurobiol* 6(5): 661-6.
- Beal M.F. (2000). Energetics in the pathogenesis of neurodegenerative diseases. *Trends Neurosci* 23(7): 298-304.
- Beckman K.B. y Ames B.N. (1998). Mitochondrial aging: open questions. *Ann N Y Acad Sci* 854: 118-27.
- Behl C. (1999). Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. *Prog Neurobiol* 57(3): 301-23.
- Bennett M.C., Diamond D.M., Stryker S.L., Parks J.K. y Parker W.D., Jr. (1992). Cytochrome oxidase inhibition: a novel animal model of Alzheimer's disease. *J Geriatr Psychiatry Neurol* 5(2): 93-101.
- Bentue-Ferrer D., Philouze V., Pape D., Reymann J.M., Allain H. y Van den Driessche J. (1989). Comparative evaluation of scavenger properties of exifone, piracetam and vinburnine. *Fundam Clin Pharmacol* 3(4): 323-8.
- Benzi G. y Moretti A. (1995). Are reactive oxygen species involved in Alzheimer's disease? *Neurobiol Aging* 16(4): 661-74.
- Berdanier C.D., Everts H.B., Hermoyian C. y Mathews C.E. (2001). Role of vitamin A in mitochondrial gene expression. *Diabetes Res Clin Pract* 54 Suppl 2: S11-27.
- Berezovska O., Jack C., McLean P., Aster J.C., Hicks C., Xia W., Wolfe M.S., Weinmaster G., Selkoe D.J. y Hyman B.T. (2000). Rapid Notch1 nuclear translocation after ligand binding depends on presenilin-associated gamma-secretase activity. *Ann N Y Acad Sci* 920: 223-6.
- Bertoli-Avella A.M., Oostra B.A. y Heutink P. (2004). Chasing genes in Alzheimer's and Parkinson's disease. *Hum Genet* 114(5): 413-38.

- Blanchard B.J., Park T., Fripp W.J., Lerman L.S. y Ingram V.M. (1993). A mitochondrial DNA deletion in normally aging and in Alzheimer brain tissue. *Neuroreport* 4(6): 799-802.
- Blass J.P. (2000). The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. *Ann N Y Acad Sci* 924: 170-83.
- Blass J.P. (2001). Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? *J Neurosci Res* 66(5): 851-6.
- Blass J.P., Baker A.C., Ko L. y Black R.S. (1990). Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. *Arch Neurol* 47(8): 864-9.
- Blass J.P. y Gibson G.E. (1991). The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. *Rev Neurol (Paris)* 147(6-7): 513-25.
- Blass J.P. y Gibson G.E. (1999). Cerebrometabolic aspects of delirium in relationship to dementia. *Dement Geriatr Cogn Disord* 10(5): 335-8.
- Bonilla E., Tanji K., Hirano M., Vu T.H., DiMauro S. y Schon E.A. (1999). Mitochondrial involvement in Alzheimer's disease. *Biochim Biophys Acta* 1410(2): 171-82.
- Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G. y Sisodia S.S. (1996). Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. *Neuron* 17(5): 1005-13.
- Bosetti F., Brizzi F., Barogi S., Mancuso M., Siciliano G., Tendi E.A., Murri L., Rapoport S.I. y Solaini G. (2002). Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. *Neurobiol Aging* 23(3): 371-6.
- Bossy-Wetzel E., Newmeyer D.D. y Green D.R. (1998). Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. *Embo J* 17(1): 37-49.
- Boveris A. (1977). Mitochondrial production of superoxide radical and hydrogen peroxide. *Adv Exp Med Biol* 78: 67-82.
- Bozner P., Grishko V., LeDoux S.P., Wilson G.L., Chyan Y.C. y Pappolla M.A. (1997). The amyloid beta protein induces oxidative damage of mitochondrial DNA. *J Neuropathol Exp Neurol* 56(12): 1356-62.
- Brierley E.J., Johnson M.A., James O.F. y Turnbull D.M. (1997). Mitochondrial involvement in the ageing process. Facts and controversies. *Mol Cell Biochem* 174(1-2): 325-8.
- Brown A.M., Kristal B.S., Effron M.S., Shestopalov A.I., Ullucci P.A., Sheu K.F., Blass J.P. y Cooper A.J. (2000). Zn²⁺ inhibits alpha-ketoglutarate-stimulated mitochondrial respiration and the isolated alpha-ketoglutarate dehydrogenase complex. *J Biol Chem* 275(18): 13441-7.
- Brown M.D., Shoffner J.M., Kim Y.L., Jun A.S., Graham B.H., Cabell M.F., Gurley D.S. y Wallace D.C. (1996). Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. *Am J Med Genet* 61(3): 283-9.
- Brunk U.T., Jones C.B. y Sohal R.S. (1992). A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. *Mutat Res* 275(3-6): 395-403.
- Busciglio J. y Yankner B.A. (1995). Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. *Nature* 378(6559): 776-9.

referencias

- Bush A.I., Masters C.L. y Tanzi R.E. (2003). Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. *Proc Natl Acad Sci U S A* 100(20): 11193-4.
- Butterfield D.A., Drake J., Pocernich C. y Castegna A. (2001). Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. *Trends Mol Med* 7(12): 548-54.
- Butterfield D.A., Yatin S.M. y Link C.D. (1999). *OXIDATIVE/ENERGY metabolism in neurodegenerative disorders*. New York, The New York academy of sciences.
- Campion D., Dumanchin C., Hannequin D., Dubois B., Belliard S., Puel M., Thomas-Anterion C., Michon A., Martin C., Charbonnier F., Raux G., Camuzat A., Penet C., Mesnage V., Martinez M., Clerget-Darpoux F., Brice A. y Frebourg T. (1999). Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. *Am J Hum Genet* 65(3): 664-70.
- Cao X. y Sudhof T.C. (2001). A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. *Science* 293(5527): 115-20.
- Cardoso S.M., Proenca M.T., Santos S., Santana I. y Oliveira C.R. (2004). Cytochrome c oxidase is decreased in Alzheimer's disease platelets. *Neurobiol Aging* 25(1): 105-10.
- Cardoso S.M., Santos S., Swerdlow R.H. y Oliveira C.R. (2001). Functional mitochondria are required for amyloid beta-mediated neurotoxicity. *Faseb J* 15(8): 1439-41.
- Carrieri G., Bonafe M., De Luca M., Rose G., Varcasia O., Bruni A., Maletta R., Nacmias B., Sorbi S., Corsonello F., Feraco E., Andreev K.F., Yashin A.I., Franceschi C. y De Benedictis G. (2001). Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. *Hum Genet* 108(3): 194-8.
- Casademont J., Miro O., Rodriguez-Santiago B., Viedma P., Blesa R. y Cardellach F. (2003). Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease. *J Neurol Sci* 206(1): 23-6.
- Casademont J., Rodríguez-Santiago B., Miro O., Beato A., S. L., Nunes V. y Cardellach F. Mitochondrial respiratory chain in brain homogenates: Activities in different brain areas in patients with Alzheimer's disease. *Aging Clinical and Experimental Research*, en prensa.
- Cash A.D., Aliev G., Siedlak S.L., Nunomura A., Fujioka H., Zhu X., Raina A.K., Vinters H.V., Tabaton M., Johnson A.B., Paula-Barbosa M., Avila J., Jones P.K., Castellani R.J., Smith M.A. y Perry G. (2003). Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. *Am J Pathol* 162(5): 1623-7.
- Casley C.S., Canevari L., Land J.M., Clark J.B. y Sharpe M.A. (2002a). Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. *J Neurochem* 80(1): 91-100.
- Casley C.S., Land J.M., Sharpe M.A., Clark J.B., Duchon M.R. y Canevari L. (2002b). Beta-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. *Neurobiol Dis* 10(3): 258-67.
- Cassarino D.S. y Bennett J.P., Jr. (1999). An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. *Brain Res Brain Res Rev* 29(1): 1-25.
- Cassarino D.S., Swerdlow R.H., Parks J.K., Parker W.D., Jr. y Bennett J.P., Jr. (1998). Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. *Biochem Biophys Res Commun* 248(1): 168-73.

- Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R. y Butterfield D.A. (2002a). Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. *Free Radic Biol Med* 33(4): 562-71.
- Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R. y Butterfield D.A. (2002b). Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. *J Neurochem* 82(6): 1524-32.
- Castegna A., Thongboonkerd V., Klein J.B., Lynn B., Markesbery W.R. y Butterfield D.A. (2003). Proteomic identification of nitrated proteins in Alzheimer's disease brain. *J Neurochem* 85(6): 1394-401.
- Castellani R., Hirai K., Aliev G., Drew K.L., Nunomura A., Takeda A., Cash A.D., Obrenovich M.E., Perry G. y Smith M.A. (2002). Role of mitochondrial dysfunction in Alzheimer's disease. *J Neurosci Res* 70(3): 357-60.
- Castellani R.J., Harris P.L., Sayre L.M., Fujii J., Taniguchi N., Vitek M.P., Founds H., Atwood C.S., Perry G. y Smith M.A. (2001). Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. *Free Radic Biol Med* 31(2): 175-80.
- Castellani R.J., Siedlak S.L., Perry G. y Smith M.A. (2000). Sequestration of iron by Lewy bodies in Parkinson's disease. *Acta Neuropathol (Berl)* 100(2): 111-4.
- Cavelier L., Jazin E.E., Eriksson I., Prince J., Bave U., Oreland L. y Gyllensten U. (1995). Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. *Genomics* 29(1): 217-24.
- CFAS- N.G.o.t.M.R.C.C.F.a.A.S.M. (2001). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. *Lancet* 357(9251): 169-75.
- Chagnon P., Gee M., Filion M., Robitaille Y., Belouchi M. y Gauvreau D. (1999). Phylogenetic analysis of the mitochondrial genome indicates significant differences between patients with Alzheimer disease and controls in a French-Canadian founder population. *Am J Med Genet* 85(1): 20-30.
- Chandrasekaran K., Giordano T., Brady D.R., Stoll J., Martin L.J. y Rapoport S.I. (1994). Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. *Brain Res Mol Brain Res* 24(1-4): 336-40.
- Chandrasekaran K., Hatanpaa K., Rapoport S.I. y Brady D.R. (1997). Decreased expression of nuclear and mitochondrial DNA-encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease. *Brain Res Mol Brain Res* 44(1): 99-104.
- Chang S.W., Zhang D., Chung H.D. y Zassenhaus H.P. (2000). The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain. *Biochem Biophys Res Commun* 273(1): 203-8.
- Chinnery P.F., Taylor G.A., Howell N., Andrews R.M., Morris C.M., Taylor R.W., McKeith I.G., Perry R.H., Edwardson J.A. y Turnbull D.M. (2000). Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. *Neurology* 55(2): 302-4.
- Chinnery P.F., Taylor G.A., Howell N., Brown D.T., Parsons T.J. y Turnbull D.M. (2001). Point mutations of the mtDNA control region in normal and neurodegenerative human brains. *Am J Hum Genet* 68(2): 529-32.

referencias

- Chomczynski P. y Sacchi N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162(1): 156-9.
- Christen Y. (2000). Oxidative stress and Alzheimer disease. *Am J Clin Nutr* 71(2): 621S-629S.
- Chui H.C., Tierney M., Zarow C., Lewis A., Sobel E. y Perlmutter L.S. (1993). Neuropathologic diagnosis of Alzheimer disease: interrater reliability in the assessment of senile plaques and neurofibrillary tangles. *Alzheimer Dis Assoc Disord* 7(1): 48-54.
- Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George Hyslop P. y Selkoe D.J. (1997). Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. *Nat Med* 3(1): 67-72.
- Clark R.F., Hutton M., Talbot C., Wragg M., Lendon C., Busfield F., Han S.W., Perez-Tur J., Adams M., Fuldner R., Roberts G., Karran E., Hardy J. y Goate A. (1996). The role of presenilin 1 in the genetics of Alzheimer's disease. *Cold Spring Harb Symp Quant Biol* 61: 551-8.
- Connor J.R., Snyder B.S., Arosio P., Loeffler D.A. y LeWitt P. (1995). A quantitative analysis of isoferitins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. *J Neurochem* 65(2): 717-24.
- Cooper A.J. y Kristal B.S. (1997). Multiple roles of glutathione in the central nervous system. *Biol Chem* 378(8): 793-802.
- Cooper J.M., Mann V.M. y Schapira A.H. (1992). Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. *J Neurol Sci* 113(1): 91-8.
- Cooper J.M., Wischik C. y Schapira A.H. (1993). Mitochondrial function in Alzheimer's disease. *Lancet* 341(8850): 969-70.
- Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Jr., Rimmler J.B., Locke P.A., Conneally P.M., Schmechel K.E. y et al. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat Genet* 7(2): 180-4.
- Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L. y Pericak-Vance M.A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261(5123): 921-3.
- Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., McKee A.C., Beal M.F., Graham B.H. y Wallace D.C. (1994). Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. *Genomics* 23(2): 471-6.
- Cortopassi G. y Wang E. (1995). Modelling the effects of age-related mtDNA mutation accumulation; complex I deficiency, superoxide and cell death. *Biochim Biophys Acta* 1271(1): 171-6.
- Cortopassi G.A., Shibata D., Soong N.W. y Arnheim N. (1992). A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. *Proc Natl Acad Sci U S A* 89(16): 7370-4.
- Coskun P.E., Beal M.F. y Wallace D.C. (2004). Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. *Proc Natl Acad Sci U S A* 101(29): 10726-31.
- Coskun P.E., Ruiz-Pesini E. y Wallace D.C. (2003). Control region mtDNA variants: longevity, climatic adaptation, and a forensic conundrum. *Proc Natl Acad Sci U S A* 100(5): 2174-6.

- Cotman C.W. y Berchtold N.C. (2002). Exercise: a behavioral intervention to enhance brain health and plasticity. *Trends Neurosci* 25(6): 295-301.
- Cras P., Smith M.A., Richey P.L., Siedlak S.L., Mulvihill P. y Perry G. (1995). Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. *Acta Neuropathol (Berl)* 89(4): 291-5.
- Crook R., Verkkoniemi A., Perez-Tur J., Mehta N., Baker M., Houlden H., Farrer M., Hutton M., Lincoln S., Hardy J., Gwinn K., Somer M., Paetau A., Kalimo H., Ylikoski R., Poyhonen M., Kucera S. y Haltia M. (1998). A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. *Nat Med* 4(4): 452-5.
- Curti D., Rognoni F., Gasparini L., Cattaneo A., Paolillo M., Racchi M., Zani L., Bianchetti A., Trabucchi M., Bergamaschi S. y Govoni S. (1997). Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients. *Neurosci Lett* 236(1): 13-6.
- Das P., Murphy M.P., Younkin L.H., Younkin S.G. y Golde T.E. (2001). Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. *Neurobiol Aging* 22(5): 721-7.
- Davis D.G., Schmitt F.A., Wekstein D.R. y Markesbery W.R. (1999). Alzheimer neuropathologic alterations in aged cognitively normal subjects. *J Neuropathol Exp Neurol* 58(4): 376-88.
- Davis J.N., 2nd y Parker W.D., Jr. (1998). Evidence that two reports of mtDNA cytochrome c oxidase "mutations" in Alzheimer's disease are based on nDNA pseudogenes of recent evolutionary origin. *Biochem Biophys Res Commun* 244(3): 877-83.
- Davis R.E., Miller S., Herrstadt C., Ghosh S.S., Fahy E., Shinobu L.A., Galasko D., Thal L.J., Beal M.F., Howell N. y Parker W.D., Jr. (1997). Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. *Proc Natl Acad Sci U S A* 94(9): 4526-31.
- Dawson V.L., Kizushi V.M., Huang P.L., Snyder S.H. y Dawson T.M. (1996). Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. *J Neurosci* 16(8): 2479-87.
- De Benedictis G., Rose G., Carrieri G., De Luca M., Falcone E., Passarino G., Bonafe M., Monti D., Baggio G., Bertolini S., Mari D., Mattace R. y Franceschi C. (1999). Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. *Faseb J* 13(12): 1532-6.
- De Jonghe C., Esselens C., Kumar-Singh S., Craessaerts K., Serneels S., Checler F., Annaert W., Van Broeckhoven C. y De Strooper B. (2001). Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. *Hum Mol Genet* 10(16): 1665-71.
- DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M. y Holtzman D.M. (2001). Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A* 98(15): 8850-5.
- Diaz Brinton R. y Yamazaki R.S. (1998). Advances and challenges in the prevention and treatment of Alzheimer's disease. *Pharm Res* 15(3): 386-98.
- DiMauro S., Bonilla E., Lee C.P., Schotland D.L., Scarpa A., Conn H., Jr. y Chance B. (1976). Luft's disease. Further biochemical and ultrastructural studies of skeletal muscle in the second case. *J Neurol Sci* 27(2): 217-32.

referencias

- Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S. y Rothstein J.D. (2002). Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. *Ann Neurol* 52(6): 771-8.
- Droge W. (2002). Free radicals in the physiological control of cell function. *Physiol Rev* 82(1): 47-95.
- Duchen M.R. (1999). Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death. *J Physiol* 516 (Pt 1): 1-17.
- Dugan L.L., Sensi S.L., Canzoniero L.M., Handran S.D., Rothman S.M., Lin T.S., Goldberg M.P. y Choi D.W. (1995). Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. *J Neurosci* 15(10): 6377-88.
- Eckert A., Keil U., Marques C.A., Bonert A., Frey C., Schussel K. y Muller W.E. (2003). Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. *Biochem Pharmacol* 66(8): 1627-34.
- Edland S.D., Tobe V.O., Rieder M.J., Bowen J.D., McCormick W., Teri L., Schellenberg G.D., Larson E.B., Nickerson D.A. y Kukull W.A. (2002). Mitochondrial genetic variants and Alzheimer disease: a case-control study of the T4336C and G5460A variants. *Alzheimer Dis Assoc Disord* 16(1): 1-7.
- Egensperger R., Kosel S., Schnopp N.M., Mehraein P. y Graeber M.B. (1997). Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases. *Neuropathol Appl Neurobiol* 23(4): 315-21.
- Eiserich J.P., Estevez A.G., Bamberg T.V., Ye Y.Z., Chumley P.H., Beckman J.S. y Freeman B.A. (1999). Microtubule dysfunction by posttranslational nitrotyrosination of alpha-tubulin: a nitric oxide-dependent mechanism of cellular injury. *Proc Natl Acad Sci U S A* 96(11): 6365-70.
- Elson J.L., Andrews R.M., Chinnery P.F., Lightowlers R.N., Turnbull D.M. y Howell N. (2001). Analysis of European mtDNAs for recombination. *Am J Hum Genet* 68(1): 145-153.
- Emerit J., Edeas M. y Bricaire F. (2004). Neurodegenerative diseases and oxidative stress. *Biomed Pharmacother* 58(1): 39-46.
- Enriquez J.A., Fernandez-Silva P., Garrido-Perez N., Lopez-Perez M.J., Perez-Martos A. y Montoya J. (1999). Direct regulation of mitochondrial RNA synthesis by thyroid hormone. *Mol Cell Biol* 19(1): 657-70.
- Esiri M.M. (2001). Is an effective immune intervention for Alzheimer's disease in prospect? *Trends Pharmacol Sci* 22(1): 2-3.
- Esler W.P. y Wolfe M.S. (2001). A portrait of Alzheimer secretases--new features and familiar faces. *Science* 293(5534): 1449-54.
- Espinosa R., 3rd, Lemons R.S., Perlman R.K., Kuo W.L., Rosner M.R. y Le Beau M.M. (1991). Localization of the gene encoding insulin-degrading enzyme to human chromosome 10, bands q23---q25. *Cytogenet Cell Genet* 57(4): 184-6.
- Eyre-Walker A. y Awadalla P. (2001). Does human mtDNA recombine? *J Mol Evol* 53(4-5): 430-5.
- Fahy E., Nazarbaghi R., Zomorodi M., Herrnstadt C., Parker W.D., Davis R.E. y Ghosh S.S. (1997). Multiplex fluorescence-based primer extension method for quantitative mutation analysis of mitochondrial DNA and its diagnostic application for Alzheimer's disease. *Nucleic Acids Res* 25(15): 3102-9.

- Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N. y van Duijn C.M. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *Jama* 278(16): 1349-56.
- Floyd R.A. y Hensley K. (2002). Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. *Neurobiol Aging* 23(5): 795-807.
- Fukuyama H., Ogawa M., Yamauchi H., Yamaguchi S., Kimura J., Yonekura Y. y Konishi J. (1994). Altered cerebral energy metabolism in Alzheimer's disease: a PET study. *J Nucl Med* 35(1): 1-6.
- Gabuzda D., Busciglio J., Chen L.B., Matsudaira P. y Yankner B.A. (1994). Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. *J Biol Chem* 269(18): 13623-8.
- Garcia-Lozano J.R., Mir P., Alberca R., Aguilera I., Gil Neciga E., Fernandez-Lopez O., Cayuela A. y Nunez-Roldan A. (2002). Mitochondrial DNA A4336G mutation in Alzheimer's and Parkinson's diseases. *Eur Neurol* 48(1): 34-6.
- Ghosh S.S., Swerdlow R.H., Miller S.W., Sheeman B., Parker W.D., Jr. y Davis R.E. (1999). Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. *Ann N Y Acad Sci* 893: 176-91.
- Gibson G.E., Pulsinelli W., Blass J.P. y Duffy T.E. (1981). Brain dysfunction in mild to moderate hypoxia. *Am J Med* 70(6): 1247-54.
- Gibson G.E., Vestling M., Zhang H., Szolosi S., Alkon D., Lannfelt L., Gandy S. y Cowburn R.F. (1997). Abnormalities in Alzheimer's disease fibroblasts bearing the APP670/671 mutation. *Neurobiol Aging* 18(6): 573-80.
- Giles R.E., Blanc H., Cann H.M. y Wallace D.C. (1980). Maternal inheritance of human mitochondrial DNA. *Proc Natl Acad Sci U S A* 77(11): 6715-9.
- Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L. y et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 349(6311): 704-6.
- Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E. y Hyman B.T. (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann Neurol* 41(1): 17-24.
- Gong C.X., Singh T.J., Grundke-Iqbal I. y Iqbal K. (1993). Phosphoprotein phosphatase activities in Alzheimer disease brain. *J Neurochem* 61(3): 921-7.
- Good P.F., Werner P., Hsu A., Olanow C.W. y Perl D.P. (1996). Evidence of neuronal oxidative damage in Alzheimer's disease. *Am J Pathol* 149(1): 21-8.
- Graham B.H., Waymire K.G., Cottrell B., Trounce I.A., MacGregor G.R. y Wallace D.C. (1997). A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. *Nat Genet* 16(3): 226-34.
- Gu G., Reyes P.E., Golden G.T., Woltjer R.L., Hulette C., Montine T.J. y Zhang J. (2002). Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders. *J Neuropathol Exp Neurol* 61(7): 634-9.
- Haass C. y De Strooper B. (1999). The presenilins in Alzheimer's disease--proteolysis holds the key. *Science* 286(5441): 916-9.

referencias

- Halliwell B. (1999). Antioxidant defence mechanisms: from the beginning to the end (of the beginning). *Free Radic Res* 31(4): 261-72.
- Halliwell B. y Gutteridge J. (1999). *Oxidative stress in AD*. New York, Oxford University Press.
- Hamblet N.S. y Castora F.J. (1997). Elevated levels of the Kearns-Sayre syndrome mitochondrial DNA deletion in temporal cortex of Alzheimer's patients. *Mutat Res* 379(2): 253-62.
- Han S.H., Hulette C., Saunders A.M., Einstein G., Pericak-Vance M., Strittmatter W.J., Roses A.D. y Schmechel D.E. (1994). Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. *Exp Neurol* 128(1): 13-26.
- Hardy J. (1997). Amyloid, the presenilins and Alzheimer's disease. *Trends Neurosci* 20(4): 154-9.
- Hardy J. y Selkoe D.J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297(5580): 353-6.
- Harman D. (1972). The biologic clock: the mitochondria? *J Am Geriatr Soc* 20(4): 145-7.
- Harman D. (1992). Free radical theory of aging. *Mutat Res* 275(3-6): 257-66.
- Hashimoto M., Rockenstein E., Crews L. y Masliah E. (2003). Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. *Neuromolecular Med* 4(1-2): 21-36.
- Hayashi J., Ohta S., Kikuchi A., Takemitsu M., Goto Y. y Nonaka I. (1991). Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction. *Proc Natl Acad Sci U S A* 88(23): 10614-8.
- Hayn M., Kremser K., Singewald N., Cairns N., Nemethova M., Lubec B. y Lubec G. (1996). Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease. *Life Sci* 59(7): 537-44.
- Hedley D. y Chow S. (1992). Flow cytometric measurement of lipid peroxidation in vital cells using parinaric acid. *Cytometry* 13(7): 686-92.
- Hendrie H.C., Ogunniyi A., Hall K.S., Baiyewu O., Unverzagt F.W., Gureje O., Gao S., Evans R.M., Ogunseyinde A.O., Adeyinka A.O., Musick B. y Hui S.L. (2001). Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. *Jama* 285(6): 739-47.
- Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A. y Butterfield D.A. (1994). A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. *Proc Natl Acad Sci U S A* 91(8): 3270-4.
- Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M. y et al. (1995). Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. *J Neurochem* 65(5): 2146-56.
- Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G. y Smith M.A. (2001). Mitochondrial abnormalities in Alzheimer's disease. *J Neurosci* 21(9): 3017-23.
- Hirano M., Shtilbans A., Mayeux R., Davidson M.M., DiMauro S., Knowles J.A. y Schon E.A. (1997). Apparent mtDNA heteroplasmy in Alzheimer's disease patients and in normals due to PCR

- amplification of nucleus-embedded mtDNA pseudogenes. *Proc Natl Acad Sci U S A* 94(26): 14894-9.
- Hirano M. y Vu T.H. (2000). Defects of intergenomic communication: where do we stand? *Brain Pathol* 10(3): 451-61.
- Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C. y Gonzalez M.I. (2004). Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. *Brain Res* 1017(1-2): 130-6.
- Hoyer S. (1993). Intermediary metabolism disturbance in AD/SDAT and its relation to molecular events. *Prog Neuropsychopharmacol Biol Psychiatry* 17(2): 199-228.
- Hoyer S., Lannert H., Noldner M. y Chatterjee S.S. (1999). Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). *J Neural Transm* 106(11-12): 1171-88.
- Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E. y Bush A.I. (1999). The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. *Biochemistry* 38(24): 7609-16.
- Hutchin T. y Cortopassi G. (1995). A mitochondrial DNA clone is associated with increased risk for Alzheimer disease. *Proc Natl Acad Sci U S A* 92(15): 6892-5.
- Hutchin T.P., Heath P.R., Pearson R.C. y Sinclair A.J. (1997). Mitochondrial DNA mutations in Alzheimer's disease. *Biochem Biophys Res Commun* 241(2): 221-5.
- Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joesse M., Kwon J.M., Nowotny P., Heutink P. y et al. (1998a). Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* 393(6686): 702-5.
- Hutton M., Perez-Tur J. y Hardy J. (1998b). Genetics of Alzheimer's disease. *Essays Biochem* 33: 117-31.
- Hy L.X. y Keller D.M. (2000). Prevalence of AD among whites: a summary by levels of severity. *Neurology* 55(2): 198-204.
- Inoue H., Kimura A. y Tuji T. (2002). Degradation profile of mRNA in a dead rat body: basic semi-quantification study. *Forensic Sci Int* 130(2-3): 127-32.
- Isobe K., Ito S., Hosaka H., Iwamura Y., Kondo H., Kagawa Y. y Hayashi J.I. (1998). Nuclear-recessive mutations of factors involved in mitochondrial translation are responsible for age-related respiration deficiency of human skin fibroblasts. *J Biol Chem* 273(8): 4601-6.
- Ito S., Ohta S., Nishimaki K., Kagawa Y., Soma R., Kuno S.Y., Komatsuzaki Y., Mizusawa H. y Hayashi J. (1999). Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease. *Proc Natl Acad Sci U S A* 96(5): 2099-103.
- Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N. y Ihara Y. (1994). Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). *Neuron* 13(1): 45-53.
- Jacobs H.T. (2003a). The mitochondrial theory of aging: dead or alive? *Aging Cell* 2(1): 11-7.
- Jacobs H.T. (2003b). Rebuttal to Pak et al.: new data, chestnuts. *Aging Cell* 2(1): 19-20.

referencias

- Janetzky B., Schmid C., Bischof F., Frolich L., Gsell W., Kalaria R.N., Riederer P. y Reichmann H. (1996). Investigations on the point mutations at nt 5460 of the mtDNA in different neurodegenerative and neuromuscular diseases. *Eur Neurol* 36(3): 149-53.
- Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P. y Westaway D. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. *Nature* 408(6815): 979-82.
- Jarreta D., Orus J., Barrientos A., Miro O., Roig E., Heras M., Moraes C.T., Cardellach F. y Casademont J. (2000). Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. *Cardiovasc Res* 45(4): 860-5.
- Jellinger K.A. (2003). General aspects of neurodegeneration. *J Neural Transm Suppl*(65): 101-44.
- Johnson S.A., Morgan D.G. y Finch C.E. (1986). Extensive postmortem stability of RNA from rat and human brain. *J Neurosci Res* 16(1): 267-80.
- Kajander O.A., Kunnas T.A., Perola M., Lehtinen S.K., Karhunen P.J. y Jacobs H.T. (1999a). Long-extension PCR to detect deleted mitochondrial DNA molecules is compromised by technical artefacts. *Biochem Biophys Res Commun* 254(2): 507-14.
- Kajander O.A., Poulton J., Spelbrink J.N., Rovio A., Karhunen P.J. y Jacobs H.T. (1999b). The dangers of extended PCR in the clinic. *Nat Med* 5(9): 965-6.
- Khan S.M., Cassarino D.S., Abramova N.N., Keeney P.M., Borland M.K., Trimmer P.A., Krebs C.T., Bennett J.C., Parks J.K., Swerdlow R.H., Parker W.D., Jr. y Bennett J.P., Jr. (2000). Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. *Ann Neurol* 48(2): 148-55.
- King M.P. y Attardi G. (1989). Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. *Science* 246(4929): 500-3.
- Kish S.J., Bergeron C., Rajput A., Dozic S., Mastrogiacomo F., Chang L.J., Wilson J.M., DiStefano L.M. y Nobrega J.N. (1992). Brain cytochrome oxidase in Alzheimer's disease. *J Neurochem* 59(2): 776-9.
- Kluck R.M., Bossy-Wetzel E., Green D.R. y Newmeyer D.D. (1997). The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. *Science* 275(5303): 1132-6.
- Koehler C.M., Leuenberger D., Merchant S., Renold A., Junne T. y Schatz G. (1999). Human deafness dystonia syndrome is a mitochondrial disease. *Proc Natl Acad Sci U S A* 96(5): 2141-6.
- Kogelnik A.M., Lott M.T., Brown M.D., Navathe S.B. y Wallace D.C. (1998). MITOMAP: a human mitochondrial genome database--1998 update. *Nucleic Acids Res* 26(1): 112-5.
- Kokoszka J.E., Coskun P., Esposito L.A. y Wallace D.C. (2001). Increased mitochondrial oxidative stress in the Sod2 (+/-) mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. *Proc Natl Acad Sci U S A* 98(5): 2278-83.
- Kong J. y Xu Z. (1998). Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. *J Neurosci* 18(9): 3241-50.
- Kosel S., Egensperger R., Mehraein P. y Graeber M.B. (1994). No association of mutations at nucleotide 5460 of mitochondrial NADH dehydrogenase with Alzheimer's disease. *Biochem Biophys Res Commun* 203(2): 745-9.
- Kovacs D.M., Fausett H.J., Page K.J., Kim T.W., Moir R.D., Merriam D.E., Hollister R.D., Hallmark O.G., Mancini R., Felsenstein K.M., Hyman B.T., Tanzi R.E. y Wasco W. (1996). Alzheimer-

- associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. *Nat Med* 2(2): 224-9.
- Kruman, Il, Nath A. y Mattson M.P. (1998). HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. *Exp Neurol* 154(2): 276-88.
- Kuperstein F. y Yavin E. (2002). ERK activation and nuclear translocation in amyloid-beta peptide- and iron-stressed neuronal cell cultures. *Eur J Neurosci* 16(1): 44-54.
- Lebovitz R.M., Zhang H., Vogel H., Cartwright J., Jr., Dionne L., Lu N., Huang S. y Matzuk M.M. (1996). Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. *Proc Natl Acad Sci U S A* 93(18): 9782-7.
- Lee H.C., Pang C.Y., Hsu H.S. y Wei Y.H. (1994). Differential accumulations of 4,977 bp deletion in mitochondrial DNA of various tissues in human ageing. *Biochim Biophys Acta* 1226(1): 37-43.
- Lee J., Duan W. y Mattson M.P. (2002). Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. *J Neurochem* 82(6): 1367-75.
- Lee S.C., Zhao M.L., Hirano A. y Dickson D.W. (1999). Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. *J Neuropathol Exp Neurol* 58(11): 1163-9.
- Lenaz G., Bovina C., D'Aurelio M., Fato R., Formiggini G., Genova M.L., Giuliano G., Merlo Pich M., Paolucci U., Parenti Castelli G. y Ventura B. (2002). Role of mitochondria in oxidative stress and aging. *Ann N Y Acad Sci* 959: 199-213.
- Lendon C.L., Ashall F. y Goate A.M. (1997). Exploring the etiology of Alzheimer disease using molecular genetics. *Jama* 277(10): 825-31.
- Levy S.E., Waymire K.G., Kim Y.L., MacGregor G.R. y Wallace D.C. (1999). Transfer of chloramphenicol-resistant mitochondrial DNA into the chimeric mouse. *Transgenic Res* 8(2): 137-45.
- Levy-Lahad E., Lahad A., Wijsman E.M., Bird T.D. y Schellenberg G.D. (1995). Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. *Ann Neurol* 38(4): 678-80.
- Lezza A.M., Mecocci P., Cormio A., Beal M.F., Cherubini A., Cantatore P., Senin U. y Gadaleta M.N. (1999). Mitochondrial DNA 4977 bp deletion and OH8dG levels correlate in the brain of aged subjects but not Alzheimer's disease patients. *Faseb J* 13(9): 1083-8.
- Li Y., Huang T.T., Carlson E.J., Melov S., Ursell P.C., Olson J.L., Noble L.J., Yoshimura M.P., Berger C., Chan P.H. y et al. (1995). Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. *Nat Genet* 11(4): 376-81.
- Lightowlers R.N., Jacobs H.T. y Kajander O.A. (1999). Mitochondrial DNA--all things bad? *Trends Genet* 15(3): 91-3.
- Lin F.H. y Lin R. (1992a). A comparison of single nucleotide primer extension with mispairing PCR-RFLP in detecting a point mutation. *Biochem Biophys Res Commun* 189(2): 1202-6.
- Lin F.H., Lin R., Wisniewski H.M., Hwang Y.W., Grundke-Iqbal I., Healy-Louie G. y Iqbal K. (1992b). Detection of point mutations in codon 331 of mitochondrial NADH dehydrogenase subunit 2 in Alzheimer's brains. *Biochem Biophys Res Commun* 182(1): 238-46.

referencias

- Lin M.T., Simon D.K., Ahn C.H., Kim L.M. y Beal M.F. (2002). High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. *Hum Mol Genet* 11(2): 133-45.
- Lipton S.A. y Rosenberg P.A. (1994). Excitatory amino acids as a final common pathway for neurologic disorders. *N Engl J Med* 330(9): 613-22.
- Lodish H. (1999). *Molecular Cell Biology*.
- Lovell M.A., Ehmann W.D., Butler S.M. y Markesbery W.R. (1995). Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. *Neurology* 45(8): 1594-601.
- Luft R., Ikkos D., Palmieri G., Ernster L. y Afzelius B. (1962). A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. *J Clin Invest* 41: 1776-804.
- Luft R. y Luthman H. (1993). [Physiopathology of mitochondria. From Luft's disease to aging and diabetes]. *Lakartidningen* 90(34): 2770-5.
- Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S. y Wu H. (2004). AβAD directly links Aβeta to mitochondrial toxicity in Alzheimer's disease. *Science* 304(5669): 448-52.
- Lynch T., Sano M., Marder K.S., Bell K.L., Foster N.L., Defendini R.F., Sima A.A., Keohane C., Nygaard T.G., Fahn S. y et al. (1994). Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. *Neurology* 44(10): 1878-84.
- Lyras L., Cairns N.J., Jenner A., Jenner P. y Halliwell B. (1997). An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. *J Neurochem* 68(5): 2061-9.
- Mahley R.W. (1988). Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* 240(4852): 622-30.
- Mahley R.W. y Rall S.C., Jr. (2000). Apolipoprotein E: far more than a lipid transport protein. *Annu Rev Genomics Hum Genet* 1: 507-37.
- Mancuso M., Filosto M., Bosetti F., Ceravolo R., Rocchi A., Tognoni G., Manca M.L., Solaini G., Siciliano G. y Murri L. (2003). Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. *Exp Neurol* 182(2): 421-6.
- Manczak M., Park B.S., Jung Y. y Reddy P.H. (2004). Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. *Neuromolecular Med* 5(2): 147-62.
- Marcus D.L., Thomas C., Rodriguez C., Simberkoff K., Tsai J.S., Strafacci J.A. y Freedman M.L. (1998). Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. *Exp Neurol* 150(1): 40-4.
- Mark R.J., Lovell M.A., Markesbery W.R., Uchida K. y Mattson M.P. (1997). A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. *J Neurochem* 68(1): 255-64.
- Markesbery W.R. (1997). Oxidative stress hypothesis in Alzheimer's disease. *Free Radic Biol Med* 23(1): 134-47.

- Martins R.N., Harper C.G., Stokes G.B. y Masters C.L. (1986). Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. *J Neurochem* 46(4): 1042-5.
- Masliah E. y Licastro F. (2000). *Neuronal and synaptic loss, reactive gliosis, microglial response and induction of the complement cascade in Alzheimer's disease*. New York, McGraw-Hill.
- Mattson M.P. (1994). Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. *Ann N Y Acad Sci* 747: 50-76.
- Mattson M.P. (1995). Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid beta-peptide? *Neurobiol Aging* 16(4): 679-82; discussion 683.
- Mattson M.P. (1997). Advances fuel Alzheimer's conundrum. *Nat Genet* 17(3): 254-6.
- Mattson M.P. (2003). Gene-diet interactions in brain aging and neurodegenerative disorders. *Ann Intern Med* 139(5 Pt 2): 441-4.
- Mattson M.P. y Liu D. (2002). Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. *Neuromolecular Med* 2(2): 215-31.
- Mattson M.P., Lovell M.A., Furukawa K. y Markesbery W.R. (1995). Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca²⁺ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. *J Neurochem* 65(4): 1740-51.
- Maurer I., Zierz S. y Moller H.J. (2000). A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. *Neurobiol Aging* 21(3): 455-62.
- Maurizi C.P. (2001). Alzheimer's disease: roles for mitochondrial damage, the hydroxyl radical, and cerebrospinal fluid deficiency of melatonin. *Med Hypotheses* 57(2): 156-60.
- Mayeux R. (2003). Epidemiology of neurodegeneration. *Annu Rev Neurosci* 26: 81-104.
- McGeer P.L. y McGeer E. (2003). Is there a future for vaccination as a treatment for Alzheimer's disease? *Neurobiol Aging* 24(3): 391-5.
- McKhann G., Drachman D., Folstein M., Katzman R., Price D. y Stadlan E.M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 34(7): 939-44.
- Mecocci P., Beal M.F., Cecchetti R., Polidori M.C., Cherubini A., Chionne F., Avellini L., Romano G. y Senin U. (1997). Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. *Mol Chem Neuropathol* 31(1): 53-64.
- Mecocci P., MacGarvey U. y Beal M.F. (1994). Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. *Ann Neurol* 36(5): 747-51.
- Melov S. (2000). Mitochondrial oxidative stress. Physiologic consequences and potential for a role in aging. *Ann N Y Acad Sci* 908: 219-25.
- Michikawa Y., Mazzucchelli F., Bresolin N., Scarlato G. y Attardi G. (1999). Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. *Science* 286(5440): 774-9.

referencias

- Miller S.W., Trimmer P.A., Parker W.D., Jr. y Davis R.E. (1996). Creation and characterization of mitochondrial DNA-depleted cell lines with "neuronal-like" properties. *J Neurochem* 67(5): 1897-907.
- Milward E.A., Papadopoulos R., Fuller S.J., Moir R.D., Small D., Beyreuther K. y Masters C.L. (1992). The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. *Neuron* 9(1): 129-37.
- Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L. y Kuhl D.E. (1997). Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. *Ann Neurol* 42(1): 85-94.
- Miquel J., Economos A.C., Fleming J. y Johnson J.E., Jr. (1980). Mitochondrial role in cell aging. *Exp Gerontol* 15(6): 575-91.
- Miro O., Cardellach F., Barrientos A., Casademont J., Rotig A. y Rustin P. (1998). Cytochrome c oxidase assay in minute amounts of human skeletal muscle using single wavelength spectrophotometers. *J Neurosci Methods* 80(1): 107-11.
- Miyata M. y Smith J.D. (1996). Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. *Nat Genet* 14(1): 55-61.
- Molina J.A., de Bustos F., Jimenez-Jimenez F.J., Benito-Leon J., Gasalla T., Orti-Pareja M., Vela L., Bermejo F., Martin M.A., Campos Y. y Arenas J. (1997). Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease. *Neurology* 48(3): 636-8.
- Montine K.S., Quinn J.F., Zhang J., Fessel J.P., Roberts L.J., 2nd, Morrow J.D. y Montine T.J. (2004). Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. *Chem Phys Lipids* 128(1-2): 117-24.
- Montine T.J., Markesbery W.R., Morrow J.D. y Roberts L.J., 2nd (1998). Cerebrospinal fluid F2-isopropane levels are increased in Alzheimer's disease. *Ann Neurol* 44(3): 410-3.
- Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M. y Arendash G.W. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. *Nature* 408(6815): 982-5.
- Morsch R., Simon W. y Coleman P.D. (1999). Neurons may live for decades with neurofibrillary tangles. *J Neuropathol Exp Neurol* 58(2): 188-97.
- Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R., Koss E., Pfeiffer E., Jin S., Gamst A., Grundman M., Thomas R. y Thal L.J. (2000). Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. *Jama* 283(8): 1007-15.
- Munch G., Gerlach M., Sian J., Wong A. y Riederer P. (1998). Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress? *Ann Neurol* 44(3 Suppl 1): S85-8.
- Munch G., Thome J., Foley P., Schinzel R. y Riederer P. (1997). Advanced glycation endproducts in ageing and Alzheimer's disease. *Brain Res Brain Res Rev* 23(1-2): 134-43.
- Mutisya E.M., Bowling A.C. y Beal M.F. (1994). Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. *J Neurochem* 63(6): 2179-84.
- Neckelmann N., Li K., Wade R.P., Shuster R. y Wallace D.C. (1987). cDNA sequence of a human skeletal muscle ADP/ATP translocator: lack of a leader peptide, divergence from a

- fibroblast translocator cDNA, and coevolution with mitochondrial DNA genes. *Proc Natl Acad Sci U S A* 84(21): 7580-4.
- Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., Naslund J. y Lannfelt L. (2001). The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. *Nat Neurosci* 4(9): 887-93.
- Nishimoto I., Okamoto T., Matsuura Y., Takahashi S., Murayama Y. y Ogata E. (1993). Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o). *Nature* 362(6415): 75-9.
- Nitsch R.M., Blusztajn J.K., Pittas A.G., Slack B.E., Growdon J.H. y Wurtman R.J. (1992). Evidence for a membrane defect in Alzheimer disease brain. *Proc Natl Acad Sci U S A* 89(5): 1671-5.
- Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B. y Smith M.A. (2001). Oxidative damage is the earliest event in Alzheimer disease. *J Neuropathol Exp Neurol* 60(8): 759-67.
- Nunomura A., Perry G., Pappolla M.A., Friedland R.P., Hirai K., Chiba S. y Smith M.A. (2000). Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. *J Neuropathol Exp Neurol* 59(11): 1011-7.
- Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S. y Smith M.A. (1999). RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. *J Neurosci* 19(6): 1959-64.
- Nussbaum R.L. y Ellis C.E. (2003). Alzheimer's disease and Parkinson's disease. *N Engl J Med* 348(14): 1356-64.
- O'Brien J.T. y Ballard C.G. (2001). Drugs for Alzheimer's disease. *Bmj* 323(7305): 123-4.
- Ojaimi J. y Byrne E. (2001). Mitochondrial function and alzheimer's disease. *Biol Signals Recept* 10(3-4): 254-62.
- Ojaimi J., Masters C.L., Opeskin K., McKelvie P. y Byrne E. (1999). Mitochondrial respiratory chain activity in the human brain as a function of age. *Mech Ageing Dev* 111(1): 39-47.
- Orth M. y Schapira A.H. (2001). Mitochondria and degenerative disorders. *Am J Med Genet* 106(1): 27-36.
- Pak J.W., Herbst A., Bua E., Gokey N., McKenzie D. y Aiken J.M. (2003). Rebuttal to Jacobs: the mitochondrial theory of aging: alive and well. *Aging Cell* 2(1): 9-10.
- Pallotti F., Chen X., Bonilla E. y Schon E.A. (1996). Evidence that specific mtDNA point mutations may not accumulate in skeletal muscle during normal human aging. *Am J Hum Genet* 59(3): 591-602.
- Palmer A.M. (2002). Pharmacotherapy for Alzheimer's disease: progress and prospects. *Trends Pharmacol Sci* 23(9): 426-33.
- Palmer A.M. y Burns M.A. (1994). Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. *Brain Res* 645(1-2): 338-42.
- Pappolla M.A., Omar R.A., Kim K.S. y Robakis N.K. (1992). Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. *Am J Pathol* 140(3): 621-8.
- Parker W.D., Jr. (1991). Cytochrome oxidase deficiency in Alzheimer's disease. *Ann N Y Acad Sci* 640: 59-64.

referencias

- Parker W.D., Jr., Boyson S.J. y Parks J.K. (1989). Abnormalities of the electron transport chain in idiopathic Parkinson's disease. *Ann Neurol* 26(6): 719-23.
- Parker W.D., Jr., Filley C.M. y Parks J.K. (1990). Cytochrome oxidase deficiency in Alzheimer's disease. *Neurology* 40(8): 1302-3.
- Parker W.D., Jr., Mahr N.J., Filley C.M., Parks J.K., Hughes D., Young D.A. y Cullum C.M. (1994a). Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. *Neurology* 44(6): 1086-90.
- Parker W.D., Jr., Parks J., Filley C.M. y Kleinschmidt-DeMasters B.K. (1994b). Electron transport chain defects in Alzheimer's disease brain. *Neurology* 44(6): 1090-6.
- Payami H., Zarepari S., Montee K.R., Sexton G.J., Kaye J.A., Bird T.D., Yu C.E., Wijsman E.M., Heston L.L., Litt M. y Schellenberg G.D. (1996). Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. *Am J Hum Genet* 58(4): 803-11.
- Peacock M.L., Murman D.L., Sima A.A., Warren J.T., Jr., Roses A.D. y Fink J.K. (1994). Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late-onset Alzheimer's disease. *Ann Neurol* 35(4): 432-8.
- Pellegrini L., Passer B.J., Tabaton M., Ganjei J.K. y D'Adamio L. (1999). Alternative, non-secretase processing of Alzheimer's beta-amyloid precursor protein during apoptosis by caspase-6 and -8. *J Biol Chem* 274(30): 21011-6.
- Perry G. y Smith M.A. (1998). Is oxidative damage central to the pathogenesis of Alzheimer disease? *Acta Neurol Belg* 98(2): 175-9.
- Petruzzella V., Chen X. y Schon E.A. (1992). Is a point mutation in the mitochondrial ND2 gene associated with Alzheimer's disease. *Biochem Biophys Res Commun* 186(1): 491-7.
- Pfaffl M.W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 29(9): e45.
- Pfaffl M.W., Horgan G.W. y Dempfle L. (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res* 30(9): e36.
- Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M. y Jucker M. (2002). Cerebral hemorrhage after passive anti-Abeta immunotherapy. *Science* 298(5597): 1379.
- Piganeau G. y Eyre-Walker A. (2004). A reanalysis of the indirect evidence for recombination in human mitochondrial DNA. *Heredity* 92(4): 282-8.
- Porteous W.K., James A.M., Sheard P.W., Porteous C.M., Packer M.A., Hyslop S.J., Melton J.V., Pang C.Y., Wei Y.H. y Murphy M.P. (1998). Bioenergetic consequences of accumulating the common 4977-bp mitochondrial DNA deletion. *Eur J Biochem* 257(1): 192-201.
- Poulton J., Deadman M.E., Bindoff L., Morten K., Land J. y Brown G. (1993). Families of mtDNA rearrangements can be detected in patients with mtDNA deletions: duplications may be a transient intermediate form. *Hum Mol Genet* 2(1): 23-30.
- Pratico D. y Sung S. (2004). Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. *J Alzheimers Dis* 6(2): 171-5.

- Pratico D., Uryu K., Leight S., Trojanoswki J.Q. y Lee V.M. (2001). Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. *J Neurosci* 21(12): 4183-7.
- Premkumar D.R., Smith M.A., Richey P.L., Petersen R.B., Castellani R., Kutty R.K., Wiggert B., Perry G. y Kalaria R.N. (1995). Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. *J Neurochem* 65(3): 1399-402.
- Prihar G., Fuldner R.A., Perez-Tur J., Lincoln S., Duff K., Crook R., Hardy J., Philips C.A., Venter C., Talbot C., Clark R.F., Goate A., Li J., Potter H., Karran E., Roberts G.W., Hutton M. y Adams M.D. (1996). Structure and alternative splicing of the presenilin-2 gene. *Neuroreport* 7(10): 1680-4.
- Racchi M. y Govoni S. (1999). Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism. *Trends Pharmacol Sci* 20(10): 418-23.
- Ramassamy C., Averill D., Beffert U., Bastianetto S., Theroux L., Lussier-Cacan S., Cohn J.S., Christen Y., Davignon J., Quirion R. y Poirier J. (1999). Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. *Free Radic Biol Med* 27(5-6): 544-53.
- Ray W.J., Ashall F. y Goate A.M. (1998). Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease. *Mol Med Today* 4(4): 151-7.
- Reichmann H., Florke S., Hebenstreit G., Schrubar H. y Riederer P. (1993). Analyses of energy metabolism and mitochondrial genome in post-mortem brain from patients with Alzheimer's disease. *J Neurol* 240(6): 377-80.
- Reynolds I.J. y Hastings T.G. (1995). Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. *J Neurosci* 15(5 Pt 1): 3318-27.
- Rodriguez Santiago B., Casademont J. y Nunes V. (2001). [Is there a relation between Alzheimer s disease and defects of mitochondrial DNA?]. *Rev Neurol* 33(4): 301-5.
- Rodriguez-Santiago B., Casademont J. y Nunes V. (2001). Is mitochondrial DNA depletion involved in Alzheimer's disease? *Eur J Hum Genet* 9(4): 279-85.
- Rodriguez-Santiago B. y Nunes V. Expression of mitochondrial genes and transcription estimation in different brain areas in Alzheimer's disease patients. *Neurobiol Disease*, en prensa.
- Rosenberg R.N. (2000). The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. *Neurology* 54(11): 2045-54.
- Rossner S., Ueberham U., Schliebs R., Perez-Polo J.R. y Bigl V. (1998). The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. *Prog Neurobiol* 56(5): 541-69.
- Roubertoux P.L., Sluyter F., Carlier M., Marcet B., Maarouf-Veray F., Cherif C., Marican C., Arrechi P., Godin F., Jamon M., Verrier B. y Cohen-Salmon C. (2003). Mitochondrial DNA modifies cognition in interaction with the nuclear genome and age in mice. *Nat Genet* 35(1): 65-9.
- Ruiz-Pesini E., Mishmar D., Brandon M., Procaccio V. y Wallace D.C. (2004). Effects of purifying and adaptive selection on regional variation in human mtDNA. *Science* 303(5655): 223-6.
- Russell R.L., Siedlak S.L., Raina A.K., Bautista J.M., Smith M.A. y Perry G. (1999). Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. *Arch Biochem Biophys* 370(2): 236-9.

referencias

- Rustin P., Chretien D., Bourgeron T., Gerard B., Rotig A., Saudubray J.M. y Munnich A. (1994). Biochemical and molecular investigations in respiratory chain deficiencies. *Clin Chim Acta* 228(1): 35-51.
- Saitoh T., Sundsmo M., Roch J.M., Kimura N., Cole G., Schubert D., Oltersdorf T. y Schenk D.B. (1989). Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. *Cell* 58(4): 615-22.
- Sanan D.A., Weisgraber K.H., Russell S.J., Mahley R.W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A.D. y et al. (1994). Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. *J Clin Invest* 94(2): 860-9.
- Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S. y Thal L.J. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. *N Engl J Med* 336(17): 1216-22.
- Sayre L.M., Zelasko D.A., Harris P.L., Perry G., Salomon R.G. y Smith M.A. (1997). 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. *J Neurochem* 68(5): 2092-7.
- Scandalios J.G. (2002). Oxidative stress responses--what have genome-scale studies taught us? *Genome Biol* 3(7): REVIEWS1019.
- Schachter F., Faure-Delanef L., Guenot F., Rouger H., Froguel P., Lesueur-Ginot L. y Cohen D. (1994). Genetic associations with human longevity at the APOE and ACE loci. *Nat Genet* 6(1): 29-32.
- Schagger H. y Ohm T.G. (1995). Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. *Eur J Biochem* 227(3): 916-21.
- Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandeventer C., Walker S., Wogulis M., Yednock T., Games D. y Seubert P. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* 400(6740): 173-7.
- Scheuerle A., Pavenstaedt I., Schlenk R., Melzner I., Rodel G. y Haferkamp O. (1993). In situ autolysis of mouse brain: ultrastructure of mitochondria and the function of oxidative phosphorylation and mitochondrial DNA. *Virchows Arch B Cell Pathol Incl Mol Pathol* 63(6): 331-4.
- Schnopp N.M., Kosel S., Egensperger R. y Graeber M.B. (1996). Regional heterogeneity of mtDNA heteroplasmy in parkinsonian brain. *Clin Neuropathol* 15(6): 348-52.
- Schon E.A., Bonilla E. y DiMauro S. (1997). Mitochondrial DNA mutations and pathogenesis. *J Bioenerg Biomembr* 29(2): 131-49.
- Schon E.A. y Manfredi G. (2003). Neuronal degeneration and mitochondrial dysfunction. *J Clin Invest* 111(3): 303-12.
- Schon E.A., Shoubridge E.A. y Moraes C.T. (1998). Cybrids in Alzheimer's disease: a cellular model of the disease? *Neurology* 51(1): 326-7.
- Selkoe D.J. (1999). Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature* 399(6738 Suppl): A23-31.

- Selkoe D.J. (2002). Alzheimer's disease is a synaptic failure. *Science* 298(5594): 789-91.
- Shadel G.S. y Clayton D.A. (1997). Mitochondrial DNA maintenance in vertebrates. *Annu Rev Biochem* 66: 409-35.
- Shastry B.S. y Giblin F.J. (1999). Genes and susceptible loci of Alzheimer's disease. *Brain Res Bull* 48(2): 121-7.
- Sheehan J.P., Swerdlow R.H., Miller S.W., Davis R.E., Parks J.K., Parker W.D. y Tuttle J.B. (1997). Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. *J Neurosci* 17(12): 4612-22.
- Shen C.C., Wertelecki W., Driggers W.J., LeDoux S.P. y Wilson G.L. (1995). Repair of mitochondrial DNA damage induced by bleomycin in human cells. *Mutat Res* 337(1): 19-23.
- Shen J., Bronson R.T., Chen D.F., Xia W., Selkoe D.J. y Tonegawa S. (1997). Skeletal and CNS defects in Presenilin-1-deficient mice. *Cell* 89(4): 629-39.
- Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C. y Westendorp R.G. (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 360(9346): 1623-30.
- Sherwin B.B. (2002). Estrogen and cognitive aging in women. *Trends Pharmacol Sci* 23(11): 527-34.
- Shoffner J.M., Brown M.D., Torroni A., Lott M.T., Cabell M.F., Mirra S.S., Beal M.F., Yang C.C., Gearing M., Salvo R. y et al. (1993). Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. *Genomics* 17(1): 171-84.
- Siest G., Pillot T., Regis-Bailly A., Leininger-Muller B., Steinmetz J., Galteau M.M. y Visvikis S. (1995). Apolipoprotein E: an important gene and protein to follow in laboratory medicine. *Clin Chem* 41(8 Pt 1): 1068-86.
- Simon D.K., Lin M.T., Ahn C.H., Liu G.J., Gibson G.E., Beal M.F. y Johns D.R. (2001). Low mutational burden of individual acquired mitochondrial DNA mutations in brain. *Genomics* 73(1): 113-6.
- Simonian N.A. y Hyman B.T. (1994). Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. *J Neuropathol Exp Neurol* 53(5): 508-12.
- Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G. y Simons K. (1998). Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. *Proc Natl Acad Sci U S A* 95(11): 6460-4.
- Sims N.R. (1996). Energy metabolism, oxidative stress and neuronal degeneration in Alzheimer's disease. *Neurodegeneration* 5(4): 435-40.
- Sims N.R., Finegan J.M., Blass J.P., Bowen D.M. y Neary D. (1987). Mitochondrial function in brain tissue in primary degenerative dementia. *Brain Res* 436(1): 30-8.
- Smith M.A., Drew K.L., Nunomura A., Takeda A., Hirai K., Zhu X., Atwood C.S., Raina A.K., Rottkamp C.A., Sayre L.M., Friedland R.P. y Perry G. (2002). Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? *Neurochem Int* 40(6): 527-31.
- Smith M.A., Harris P.L., Sayre L.M. y Perry G. (1997a). Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. *Proc Natl Acad Sci U S A* 94(18): 9866-8.

referencias

- Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F. y Kowall N. (1996). Oxidative damage in Alzheimer's. *Nature* 382(6587): 120-1.
- Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S. y Perry G. (1997b). Widespread peroxynitrite-mediated damage in Alzheimer's disease. *J Neurosci* 17(8): 2653-7.
- Smith M.A., Rottkamp C.A., Nunomura A., Raina A.K. y Perry G. (2000). Oxidative stress in Alzheimer's disease. *Biochim Biophys Acta* 1502(1): 139-44.
- Smith M.A., Sayre L.M., Monnier V.M. y Perry G. (1995). Radical AGEing in Alzheimer's disease. *Trends Neurosci* 18(4): 172-6.
- Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., Sayre L.M., Monnier V.M. y Perry G. (1994). Advanced Maillard reaction end products are associated with Alzheimer disease pathology. *Proc Natl Acad Sci U S A* 91(12): 5710-4.
- Snowdon D.A. (2003). Healthy aging and dementia: findings from the Nun Study. *Ann Intern Med* 139(5 Pt 2): 450-4.
- Sorbi S., Nacmias B., Forleo P., Piacentini S., Latorraca S. y Amaducci L. (1995). Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. *Ann Neurol* 38(1): 124-7.
- St George-Hyslop P.H. (2000). Molecular genetics of Alzheimer's disease. *Biol Psychiatry* 47(3): 183-99.
- St John J.C. y Schatten G. (2004). Paternal mitochondrial DNA transmission during nonhuman primate nuclear transfer. *Genetics* 167(2): 897-905.
- Stamer K., Vogel R., Thies E., Mandelkow E. y Mandelkow E.M. (2002). Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. *J Cell Biol* 156(6): 1051-63.
- Stewart P.A., Hayakawa K., Akers M.A. y Vinters H.V. (1992). A morphometric study of the blood-brain barrier in Alzheimer's disease. *Lab Invest* 67(6): 734-42.
- Stewart W.F., Kawas C., Corrada M. y Metter E.J. (1997). Risk of Alzheimer's disease and duration of NSAID use. *Neurology* 48(3): 626-32.
- Stierum R.H., Dianov G.L. y Bohr V.A. (1999). Single-nucleotide patch base excision repair of uracil in DNA by mitochondrial protein extracts. *Nucleic Acids Res* 27(18): 3712-9.
- Strittmatter W.J. y Roses A.D. (1996). Apolipoprotein E and Alzheimer's disease. *Annu Rev Neurosci* 19: 53-77.
- Strittmatter W.J., Weisgraber K.H., Goedert M., Saunders A.M., Huang D., Corder E.H., Dong L.M., Jakes R., Alberts M.J., Gilbert J.R. y et al. (1994). Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. *Exp Neurol* 125(2): 163-71; discussion 172-4.
- Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D. y Roses A.D. (1993). Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. *Proc Natl Acad Sci U S A* 90(17): 8098-102.
- Sudoh S., Kawamura Y., Sato S., Wang R., Saido T.C., Oyama F., Sakaki Y., Komano H. y Yanagisawa K. (1998). Presenilin 1 mutations linked to familial Alzheimer's disease increase the intracellular levels of amyloid beta-protein 1-42 and its N-terminally truncated variant(s) which are generated at distinct sites. *J Neurochem* 71(4): 1535-43.

- Sutovsky P., Moreno R.D., Ramalho-Santos J., Dominko T., Simerly C. y Schatten G. (2000). Ubiquitinated sperm mitochondria, selective proteolysis, and the regulation of mitochondrial inheritance in mammalian embryos. *Biol Reprod* 63(2): 582-90.
- Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L., Jr., Eckman C., Golde T.E. y Younkin S.G. (1994). An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. *Science* 264(5163): 1336-40.
- Swerdlow R.H. y Khan S.M. (2004). A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. *Med Hypotheses* 63(1): 8-20.
- Swerdlow R.H. y Kish S.J. (2002). Mitochondria in Alzheimer's disease. *Int Rev Neurobiol* 53: 341-85.
- Swerdlow R.H., Parks J.K., Cassarino D.S., Maguire D.J., Maguire R.S., Bennett J.P., Jr., Davis R.E. y Parker W.D., Jr. (1997). Cybrids in Alzheimer's disease: a cellular model of the disease? *Neurology* 49(4): 918-25.
- Takeda A., Perry G., Abraham N.G., Dwyer B.E., Kutty R.K., Laitinen J.T., Petersen R.B. y Smith M.A. (2000a). Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. *J Biol Chem* 275(8): 5395-9.
- Takeda A., Smith M.A., Avila J., Nunomura A., Siedlak S.L., Zhu X., Perry G. y Sayre L.M. (2000b). In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. *J Neurochem* 75(3): 1234-41.
- Tamaoka A., Fukushima T., Sawamura N., Ishikawa K., Oguni E., Komatsuzaki Y. y Shoji S. (1996). Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. *J Neurol Sci* 141(1-2): 65-8.
- Tanaka M., Gong J.S., Zhang J., Yoneda M. y Yagi K. (1998). Mitochondrial genotype associated with longevity. *Lancet* 351(9097): 185-6.
- Tanno Y., Okuizumi K. y Tsuji S. (1998). mtDNA polymorphisms in Japanese sporadic Alzheimer's disease. *Neurobiol Aging* 19(1 Suppl): S47-51.
- Te Koppele J.M., Lucassen P.J., Sakke A.N., Van Asten J.G., Ravid R., Swaab D.F. y Van Bezooijen C.F. (1996). 8OHdG levels in brain do not indicate oxidative DNA damage in Alzheimer's disease. *Neurobiol Aging* 17(6): 819-26.
- Torrioni A., Schurr T.G., Yang C.C., Szathmary E.J., Williams R.C., Schanfield M.S., Troup G.A., Knowler W.C., Lawrence D.N., Weiss K.M. y et al. (1992). Native American mitochondrial DNA analysis indicates that the Amerind and the Nadene populations were founded by two independent migrations. *Genetics* 130(1): 153-62.
- Trifunovic A., Wredenberg A., Falkenberg M., Spelbrink J.N., Rovio A.T., Bruder C.E., Bohlooly Y.M., Gidlof S., Oldfors A., Wibom R., Tornell J., Jacobs H.T. y Larsson N.G. (2004). Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature* 429(6990): 417-23.
- Trimmer P.A., Keeney P.M., Borland M.K., Simon F.A., Almeida J., Swerdlow R.H., Parks J.P., Parker W.D., Jr. y Bennett J.P., Jr. (2004). Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. *Neurobiol Dis* 15(1): 29-39.
- Trimmer P.A., Swerdlow R.H., Parks J.K., Keeney P., Bennett J.P., Jr., Miller S.W., Davis R.E. y Parker W.D., Jr. (2000). Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. *Exp Neurol* 162(1): 37-50.

referencias

- Tysoe C., Robinson D., Brayne C., Denning T., Paykel E.S., Huppert F.A. y Rubinsztein D.C. (1996). The tRNA(Gln) 4336 mitochondrial DNA variant is not a high penetrance mutation which predisposes to dementia before the age of 75 years. *J Med Genet* 33(12): 1002-6.
- Utermann G., Pruin N. y Steinmetz A. (1979). Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. *Clin Genet* 15(1): 63-72.
- Van Broeckhoven C., Backhovens H., Cruts M., Martin J.J., Crook R., Houlden H. y Hardy J. (1994). APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. *Neurosci Lett* 169(1-2): 179-80.
- van der Walt J.M., Dementieva Y.A., Martin E.R., Scott W.K., Nicodemus K.K., Kroner C.C., Welsh-Bohmer K.A., Saunders A.M., Roses A.D., Small G.W., Schmechel D.E., Murali Doraiswamy P., Gilbert J.R., Haines J.L., Vance J.M. y Pericak-Vance M.A. (2004). Analysis of European mitochondrial haplogroups with Alzheimer disease risk. *Neurosci Lett* 365(1): 28-32.
- Van Zuylen A.J., Bosman G.J., Ruitenbeek W., Van Kalmthout P.J. y De Grip W.J. (1992). No evidence for reduced thrombocyte cytochrome oxidase activity in Alzheimer's disease. *Neurology* 42(6): 1246-7.
- Vancea J.E., Campenotb R.B. y Vancec D.E. (2000). The synthesis and transport of lipids for axonal growth and nerve regeneration. *Biochim Biophys Acta* 1486(1): 84-96.
- Villa A., Latasa M.J. y Pascual A. (2001). Nerve growth factor modulates the expression and secretion of beta-amyloid precursor protein through different mechanisms in PC12 cells. *J Neurochem* 77(4): 1077-84.
- Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K. y Cerami A. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. *Proc Natl Acad Sci U S A* 91(11): 4766-70.
- Wallace D.C. (1986). Mitotic segregation of mitochondrial DNAs in human cell hybrids and expression of chloramphenicol resistance. *Somat Cell Mol Genet* 12(1): 41-9.
- Wallace D.C. (1992). Mitochondrial genetics: a paradigm for aging and degenerative diseases? *Science* 256(5057): 628-32.
- Wallace D.C. (2001). Mitochondrial defects in neurodegenerative disease. *Ment Retard Dev Disabil Res Rev* 7(3): 158-66.
- Wallace D.C., Singh G., Lott M.T., Hodge J.A., Schurr T.G., Lezza A.M., Elsas L.J., 2nd y Nikoskelainen E.K. (1988). Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. *Science* 242(4884): 1427-30.
- Wallace D.C., Stugard C., Murdock D., Schurr T. y Brown M.D. (1997). Ancient mtDNA sequences in the human nuclear genome: a potential source of errors in identifying pathogenic mutations. *Proc Natl Acad Sci U S A* 94(26): 14900-5.
- Walter J., Schindzielorz A., Grunberg J. y Haass C. (1999). Phosphorylation of presenilin-2 regulates its cleavage by caspases and retards progression of apoptosis. *Proc Natl Acad Sci U S A* 96(4): 1391-6.
- Wang J., Wilhelmsson H., Graff C., Li H., Oldfors A., Rustin P., Bruning J.C., Kahn C.R., Clayton D.A., Barsh G.S., Thoren P. y Larsson N.G. (1999). Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. *Nat Genet* 21(1): 133-7.

- Weidemann A., Paliga K., Durrwang U., Reinhard F.B., Schuckert O., Evin G. y Masters C.L. (1999). Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases. *J Biol Chem* 274(9): 5823-9.
- Weisgraber K.H. (1994). Apolipoprotein E: structure-function relationships. *Adv Protein Chem* 45: 249-302.
- West M.J., Coleman P.D., Flood D.G. y Troncoso J.C. (1994). Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. *Lancet* 344(8925): 769-72.
- Wheeler D.L., Church D.M., Lash A.E., Leipe D.D., Madden T.L., Pontius J.U., Schuler G.D., Schriml L.M., Tatusova T.A., Wagner L. y Rapp B.A. (2002). Database resources of the National Center for Biotechnology Information: 2002 update. *Nucleic Acids Res* 30(1): 13-6.
- Wiesniewski T., Sigurdsson E.M., Aucuturier P. y Franglone B. (2001). *Conformation as therapeutic target in the prionoses and other neurodegenerative conditions*. Totowa, NJ, Humana Press.
- Williams M.D., Van Remmen H., Conrad C.C., Huang T.T., Epstein C.J. y Richardson A. (1998). Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. *J Biol Chem* 273(43): 28510-5.
- Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T. y Selkoe D.J. (1999). Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. *Nature* 398(6727): 513-7.
- Wolin M.S. (1996). Reactive oxygen species and vascular signal transduction mechanisms. *Microcirculation* 3(1): 1-17.
- Wong-Riley M., Antuono P., Ho K.C., Egan R., Hevner R., Liebl W., Huang Z., Rachel R. y Jones J. (1997). Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. *Vision Res* 37(24): 3593-608.
- Wragg M.A., Talbot C.J., Morris J.C., Lendon C.L. y Goate A.M. (1995). No association found between Alzheimer's disease and a mitochondrial tRNA glutamine gene variant. *Neurosci Lett* 201(2): 107-10.
- Yang Y., Geldmacher D.S. y Herrup K. (2001). DNA replication precedes neuronal cell death in Alzheimer's disease. *J Neurosci* 21(8): 2661-8.
- Young D., Lawlor P.A., Leone P., Dragunow M. y During M.J. (1999). Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. *Nat Med* 5(4): 448-53.
- Zannis V.I., Just P.W. y Breslow J.L. (1981). Human apolipoprotein E isoprotein subclasses are genetically determined. *Am J Hum Genet* 33(1): 11-24.
- Zeviani M., Servidei S., Gellera C., Bertini E., DiMauro S. y DiDonato S. (1989). An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. *Nature* 339(6222): 309-11.
- Zhang C., Liu V.W., Addessi C.L., Sheffield D.A., Linnane A.W. y Nagley P. (1998). Differential occurrence of mutations in mitochondrial DNA of human skeletal muscle during aging. *Hum Mutat* 11(5): 360-71.
- Zhu X., Raina A.K., Lee H.G., Casadesus G., Smith M.A. y Perry G. (2004). Oxidative stress signalling in Alzheimer's disease. *Brain Res* 1000(1-2): 32-9.

referencias

Zsurka G., Kalman J., Csaszar A., Rasko I., Janka Z. y Venetianer P. (1998). No mitochondrial haplotype was found to increase risk for Alzheimer's disease. *Biol Psychiatry* 44(5): 371-3.